All In Biotech

Drug Trial Radar · NCT06228846

An Phase I Study of YY001 in Patients with Advanced Solid Tumors

An Open-Label Phase I Study to Evaluate the Safety,Tolerability and Preliminary Efficacy of YY001 in Patients with Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Jan 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

16

Actual

Start

Jul 14, 2022

Primary completion

Apr 30, 2024

Study completion May 30, 2024

Sponsor

Sponsor type
Industry
First posted
Jan 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The safety and tolerability of YY001 in the treatment of patients with advanced solid tumors were evaluated, and the possible dose-limiting toxicity (DLT) and the maximum tolerated dose (MTD) or recommended phase II clinical dose (RP2D) were observed.

Conditions

  • Advanced Solid Tumor

Interventions

  • YY001Drug

    Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose limiting toxicityTime frame: Up to 24 days after the initial drug administration
  2. Maximum tolerated doseTime frame: Up to 24 days after the initial drug administration
  3. Recommended Dose for Phase II Clinical Studies (RP2D)Time frame: Up to 24 days after the initial drug administration

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai East Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.